scispace - formally typeset
T

Thomas Martin

Researcher at University of California, San Francisco

Publications -  311
Citations -  17918

Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.

Papers
More filters
Journal ArticleDOI

Characterization of phorbol ester- and diacylglycerol-stimulated secretion in permeable GH3 pituitary cells. Interaction with Ca2+.

Susan A. Ronning, +1 more
- 15 Jun 1986 - 
TL;DR: The hypothesis that PRL release in GH3 cells can be stimulated directly by a diacylglycerol-activated secretory mechanism whose activity is modulated by [Ca2+] is supported.
Journal ArticleDOI

14-3-3σ (sigma) regulates proliferation and differentiation of multipotent p63-positive cells isolated from human breastmilk

Elizabeth R. Thomas, +4 more
- 15 Jan 2011 - 
TL;DR: It is proposed that p63-postive cells from breastmilk represent a novel source of cells to model regulation of mammary gland development and tumorigenesis.
Journal ArticleDOI

The role of ptdins(4,5)p2 in exocytotic membrane fusion

Thomas Martin, +3 more
- 01 Nov 1997 - 
TL;DR: A large number of the authors believe that the current generation of scientists, particularly those in the field of bioinformatics and nano-physics, are likely to be genetically predisposed to infectious disease.
Journal ArticleDOI

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

Seema Singhal, +16 more
- 18 Nov 2011 - 
TL;DR: Overall, CFZ had a favorable safety profile in these studies and is a follow-up with more mature data compared with those presented at ASH 2010.
Journal ArticleDOI

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Jonathan L. Kaufman, +12 more
- 04 Jan 2019 - 
TL;DR: CarPan proved to be a safe and effective steroid-sparing regimen in a heavily pre-treated population of MM patients, and compares favorably with that of panobinostat and bortezomib.